managing innovation evista case morgane … maël bourguignon jonathan calvet axel caborderie

Managing Innovation Evista Case

Morgane …Maël BourguignonJonathan CalvetAxel Caborderie

SummaryI. INTRODUCTION

– Background

II. MARKET CONSTRAINTS AND PROBLEMATIC

– Threats : Generics / « Me too »

– Environmental constraints : Formularies / Laws

– Problematic

III. DEVELOPMENT PROCESS AND ORGANIZATION

– Development process / Time to Market

– « Heavyweight » management approach   

IV. CONCLUSION :

– To go Further

1876. Creation of ELI LILLY and Company by Colonel Eli Lilly, pharmaceutical chemist and Civil war veteran.

Background

1930-80. ELI LILLY continued to develop insulin product family and treatment of endocrine diseases.

Background

1920. First Blockbuster for treatment of diabetes: Insulin

Background

1950s. Development of Ceclor : top-selling antibiotic of the world.

Background

1980. Introduction of Humilin using recombinant DNA technology : improve diabetes treatment.

Background

1986. Commercialisation of Prozac : drug for central nervous system.

Background

1996. Zyprexa : Anti-psychotic for treatment of schizophrenia.

Background

1990-97. Restructuring and focus on fighting cancer and cardiovascular diseases : Launch of ReoPro, anti-platelet agent and Gemzar, oncology product.

Background

2005. Eli Lilly registered 14,6 billion $ of global revenues

Background

The problematic

Considering the increasing threats within the pharmaceutical industry, How can Eli Lilly remain competitive?

Conclusion

• Time to market : a better approach taking into account the market constraints.

• « Heavyweight » approach: give the priority to the future potential blockbuster.

Conclusion

• To go further :– Should we apply this approach to

the commercialization of new drugs ?

– On which criterions ?– For which costs ?– Should we have to delay or stop

other projects ?